Press Releases

Month Year

Month Year

Oct 13, 2020

Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial

Data in children aged 6-11 further suggest Dupixent has potential to be best-in-class treatment option
Sep 21, 2020

Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

In the overall trial population, Libtayo reduced risk of death by 32% compared to chemotherapy
Sep 18, 2020

Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO

Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a hedgehog inhibitor in a prospective trial
Sep 14, 2020

FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis

* Designation based on positive results from Part A of pivotal Phase 3 trial
Sep 10, 2020

New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A

BIVV001 is the first investigational factor VIII therapy independent of von Willebrand Factor and has the potential to transform replacement therapy for people with hemophilia A

Show per page

Print
Email page
RSS